Precision Therapies for the Treatment of Solid Tumor Cancers

At Soricimed we are using our proprietary TRPV6 peptide ligands to create a new class of targeted radioligand therapies and peptide-drug conjugates.

Our Programs About TRPV6

Our novel peptide ligands selectively target and bind to TRPV6, providing a unique carrier to deliver radioisotopes directly to cancer cells for imaging and therapy. 

Our peptide ligands target transient receptor potential vanilloid 6, TRPV6, which is a selective calcium channel overexpressed on the surface of select solid tumor cancer cells and is required for the growth, metastasis and resistance to programmed cell death.

Science Icon

Our Drug Development Programs

Learn More

Partner Icon

Partner with us

We are seeking partnerships / research collaborations for our radioligand therapy and peptide-drug conjugate platform.

Contact Us

Invest Icon

Invest

We are a private oncology-focused company. Contact us to learn about current investment opportunities for accredited investors.

More Info

Latest News & Events

More News & Events

Sign up to receive updates from Soricimed

Powered by Innovasium